-
THE REASONS FOR THE HIGHER RISK OF STROKE IN WOMen who have atrial fibrillation (AF), compared to men, is unclear, but under-treatment with warfarin has been suggested as a cause.
-
-
A new selective phosphodiesterase type 5 (PDE5) inhibitor has been approved for treating erectile dysfunction (ED). Avanafil was developed by Mitsubishi Tanabe Pharma Corporation in Japan and is manufactured in Japan and marketed by Vivus, Inc., as Stendra.
-
Vitamin D deficiency is associated with a significant risk of cardiovascular disease and reduced survival. Vitamin D supplementation improved survival, especially in patients with documented deficiency.
-
The authors concluded that systematically obtaining family history identifies more subjects with high CV risk who may benefit from more aggressive preventive interventions.
-
In a prospective study of nearly 5000 postmenopausal women, it was determined that it would take 16.8 years to develop osteoporosis in 10% of women with normal bone mineral density. The authors conclude that repeat screening in women without new risk factors can be delayed for at least 15 years.
-
Within a few years after the initiation of diagnostic X-rays, toxic effects were noted, including increased risk for skin cancer, leukemia, dermatitis, and cataracts. In this early period, doses of X-ray, especially from fluoroscopy, were high. Protective devices for patients as well as persons occupationally exposed to diagnostic radiation demonstrably reduced such adverse consequences.
-
-
The authors conclude that in patients hospitalized with myocardial infarction, women were more likely than men to present without chest pain and had higher mortality than men within the same age group.
-
Patients with hypertension and diabetes mellitus can be stratified into a lower cardiovascular risk group in the absence of coronary artery calcium.